Emerging role of polyphenolic compounds and nanocarrier systems in the prevention and treatment of diabetic neuropathy

Read full text Summarise with VIRAT
Authors: Chaithra G, Preeti khulbe, Seba Eapen
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Diabetic neuropathy (DN), particularly diabetic peripheral neuropathy (DPN), is one of the most common and debilitating complications of diabetes mellitus. Its multifactorial pathogenesis—driven by hyperglycaemia-induced oxidative stress, inflammation, mitochondrial dysfunction, advanced glycation end-products (AGEs), and microvascular insufficiency—offers several molecular targets for intervention. Polyphenols, a diverse class of plant-derived phenolic compounds (e.g., flavonoids, stilbenes, phenolic acids, and catechins), exhibit pleiotropic biological activities relevant to DN: antioxidant and free-radical scavenging, modulation of redox-sensitive transcription factors (Nrf2, NF-κB), inhibition of AGE formation, mitochondrial protection, and regulation of neuroinflammation and microglial function. Preclinical (in vitro and animal) studies consistently show neuroprotective effects for specific polyphenols—resveratrol, curcumin, epigallocatechin gallate (EGCG), quercetin, catechins and cocoa flavanols—across endpoints such as nerve conduction velocity, pain behaviours, axonal integrity, and biochemical markers of oxidative stress and inflammation. Clinical evidence is promising but mixed: some randomized trials (e.g., nano-curcumin) reported symptomatic and biochemical improvements while more recent larger/longer trials show equivocal results—highlighting challenges of bioavailability, standardization, dosing, and heterogeneity of outcome measures. Innovative delivery systems (nanoparticles, phytosome/complexes), combination approaches, and rigorously designed randomized controlled trials with standardized endpoints are needed to translate preclinical promise into clinical practice. This review synthesizes mechanisms of action, summarizes key preclinical and clinical evidence, outlines limitations, and presents recommendations for future research.

Fields of Study & Subjects

Pain Mechanisms and Treatments Phytochemicals and Antioxidant Activities Natural Antidiabetic Agents Studies

Publication details

Journal / source
International Journal of Pharmaceutical Research and Development
Volume
8
Issue
2
Pages
31–37
Publication date
1 February 2026
Language
EN